Plasminogen activators in oesophageal carcinoma

The expression of components of the plasminogen activator system was investigated in patients with oesophageal carcinoma. Tumour and normal mucosa were obtained from resected oesophageal carcinomas and antigens were measured by enzyme‐linked immunosorbent assay. Median levels of urokinase plasminogen activator (uPA) and the uPA receptor were higher in carcinoma than in matched normal mucosa (squamous cell carcinoma: uPA 4.05 versus 0.66 ng antigen per mg protein, uPA receptor 1.95 versus 0.50 ng/mg, n = 10, P < 0.05; adenocarcinoma: uPA 2.16 versus 0.61 ng/mg, uPA receptor 2.01 versus 0.49 ng/mg, n = 8, P < 0.05). Tissue plasminogen activator (tPA) level was lower than control values in squamous cell carcinoma but not in adenocarcinoma (1.97 versus 4.70 ng/mg, P < 0.05). There was no difference in plasminogen activator inhibitor (PAI) 1 level between carcinoma and normal mucosa. The PAI‐2 level was lower than that in normals in adenocarcinoma only (6.0 versus 64.77 ng/mg, P < 0.05). These data support the hypothesis that membrane‐bound uPA has a role in the breakdown of extracellular matrix in invasive oesophageal carcinoma.

[1]  N. Brünner,et al.  Prognostic impact of urokinase, urokinase receptor, and type 1 plasminogen activator inhibitor in squamous and large cell lung cancer tissue. , 1994, Cancer research.

[2]  H. Verspaget,et al.  Urokinase receptor and colorectal cancer survival , 1994, The Lancet.

[3]  B. M. Mueller,et al.  Binding of urokinase to its receptor promotes migration and invasion of human melanoma cells in vitro. , 1994, Cancer research.

[4]  T. Urano,et al.  Plasminogen activators and their inhibitors in non‐small cell lung cancer. Low content of type 2 plasminogen activator inhibitor associated with tumor dissemination , 1994, Cancer.

[5]  B. Ljung,et al.  The urokinase receptor is expressed in invasive breast cancer but not in normal breast tissue. , 1994, Cancer research.

[6]  P. Quax,et al.  Plasminogen activators, their inhibitors, and urokinase receptor emerge in late stages of melanocytic tumor progression. , 1994, The American journal of pathology.

[7]  A. Nakao,et al.  Expression of plasminogen activators and their inhibitors in human pancreatic carcinoma: immunohistochemical study. , 1993, The American journal of gastroenterology.

[8]  J. Jankun,et al.  Expression and localization of elements of the plasminogen activation system in benign breast disease and breast cancers , 1993, Journal of cellular biochemistry.

[9]  J. Soria,et al.  The plasminogen‐activation system in ovarian tumors , 1993, International journal of cancer.

[10]  J. Gris,et al.  Immunohistochemical study of tumor cell-associated plasminogen activators and plasminogen activator inhibitors in lung carcinomas. , 1993, Chest.

[11]  F. Blasi.  Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993 .

[12]  H. Verspaget,et al.  Plasminogen activators in normal tissue and carcinomas of the human oesophagus and stomach. , 1993, Gut.

[13]  Francesco Blasl.  Molecular mechanisms of protease‐mediated tumor invasiveness , 1993 .

[14]  F. Blasi.  Urokinase and urokinase receptor: A paracrine/autocrine system regulating cell migration and invasiveness , 1993, BioEssays : news and reviews in molecular, cellular and developmental biology.

[15]  E. Keshet,et al.  In vivo patterns of expression of urokinase and its inhibitor PAI-1 suggest a concerted role in regulating physiological angiogenesis. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[16]  A. Sumiyoshi,et al.  The content of urokinase‐type plasminogen activator antigen as a prognostic factor in urinary bladder cancer , 1992, International journal of cancer.

[17]  Bonnie F. Sloane,et al.  Degradation of extracellular-matrix proteins by human cathepsin B from normal and tumour tissues. , 1992, The Biochemical journal.

[18]  T. Urano,et al.  Plasminogen activator system in human breast cancer , 1992, International journal of cancer.

[19]  M. Duffy,et al.  Plasminogen activator inhibitor type 1 and 2 in human breast cancer. , 1992, Biochemical Society transactions.

[20]  H. Shimada,et al.  Inhibition of invasion and metastasis in cells transfected with an inhibitor of metalloproteinases. , 1992, Cancer research.

[21]  H. Kawanishi,et al.  Plasminogen activators in human gastric cancers: Correlation with DNA ploidy and immunohistochemical staining , 2007, International journal of cancer.

[22]  P. Quax,et al.  Imbalance of plasminogen activators and their inhibitors in human colorectal neoplasia. Implications of urokinase in colorectal carcinogenesis. , 1991, Gastroenterology.

[23]  A. Desplaces,et al.  Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. , 1991, British Journal of Cancer.

[24]  M. Ploug,et al.  Cell‐induced potentiation of the plasminogen activation system is abolished by a monoclonal antibody that recognizes the NH2‐terminal domain of the urokinase receptor , 1991, FEBS letters.

[25]  F. Blasi,et al.  Urokinase-type plasminogen activator is expressed in stromal cells and its receptor in cancer cells at invasive foci in human colon adenocarcinomas. , 1991, The American journal of pathology.

[26]  M. Duffy.  Plasminogen activators and cancer. , 1990, Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis.

[27]  H. Keer,et al.  Fibrinolysis and Cancer , 1990, Seminars in thrombosis and hemostasis.

[28]  J. Verheijen,et al.  Disturbed fibrinolysis in patients with inflammatory bowel disease. A study in blood plasma, colon mucosa, and faeces. , 1989, Gut.

[29]  S. Thorsen,et al.  Kinetics of inhibition of tissue-type and urokinase-type plasminogen activator by plasminogen-activator inhibitor type 1 and type 2. , 1988, European journal of biochemistry.

[30]  P. Gaffney,et al.  Plasminogen activators in human colorectal neoplasia. , 1986, British medical journal.

[31]  K. Danø,et al.  Plasminogen activators, tissue degradation, and cancer. , 1985, Advances in cancer research.

[32]  Liotta La.  Tumor invasion and metastases: role of the basement membrane. Warner-Lambert Parke-Davis Award lecture. , 1984, The American journal of pathology.

[33]  R. Stephens,et al.  Novel properties of human monocyte plasminogen activator. , 1984, European journal of biochemistry.